BioNTech: A €16.8 Billion Bet on Oncology That Investors Are Still Ignoring
16.06.2026 - 02:53:20 | boerse-global.de
For a company sitting on €16.8 billion in cash and running more than 25 clinical studies, BioNTech's stock looks oddly out of step with its own trajectory. The shares are changing hands at around €78.40, a full 26 percent below the 52-week peak of €105.80 and roughly 5 percent weaker since the start of 2026. That disconnect stems from a simple reality: the market is pricing in the pain of the present — shrinking COVID vaccine revenue, a leadership shake-up, and deepening losses — while assigning near-zero value to an oncology pipeline that has quietly been generating some of its strongest data in years.
The cash pile alone should give investors pause for thought. With €16.8 billion in cash and securities at the end of March, BioNTech can fund its entire oncology build-out without ever tapping equity markets. That war chest covers research spending that hit €557 million in the first quarter alone — a massive increase directed at immuno-oncology programmes including the high-profile Pumitamig, a bispecific antibody developed with Bristol Myers Squibb. The group started five new registration studies for Pumitamig in the first half of 2026, and more than 13 registrational trials are now active across the portfolio. BioNTech plans to have 15 Phase 3 studies running by year-end, with seven late-stage data readouts still due before 2027.
The scientific story has been gaining momentum. At the ASCO conference in Chicago at the turn of June, the company unveiled fresh data on several fronts. Pumitamig, when combined with chemotherapy, showed durable anti-tumour activity in lung cancer patients in the ongoing ROSETTA study — the third global dataset pointing in the same direction. Gotistobart, an antibody targeting platin-resistant ovarian cancer, produced lasting responses in heavily pre-treated patients, offering a chemotherapy-free option in a difficult-to-treat group. Meanwhile BNT326, an HER3-directed antibody-drug conjugate, delivered promising Phase 2 results both as a monotherapy and in combination with Pumitamig, and BNT111, an mRNA cancer immunotherapy for melanoma, hit its primary endpoint in Phase 2 with Phase 3 data expected by the end of 2026.
Should investors sell immediately? Or is it worth buying BioNTech?
All of that, however, is being overshadowed by the short-term numbers. BioNTech posted first-quarter revenue of just €118.1 million and a net loss of €531.9 million. The company expects COVID vaccine sales to fall further in 2026 compared to 2025, both in Europe and the US. In response, it is closing multiple production facilities by the end of 2027 and cutting roughly 1,860 jobs. Adding to the unease, founders Ugur Sahin and Özlem Türeci are leaving by the end of the year to launch a new biotech focused on next-generation mRNA technology. BioNTech will receive a minority stake in the new venture in exchange for licensing certain rights and technologies — a structural shift that changes the company's identity even if it leaves the balance sheet intact.
The technical picture reflects the standoff. The relative strength index sits at 49.7, neutral in all regards. The stock has stabilised after a rough spring, trading about 15 percent above its 52-week low of €68.35, but it remains below its 50-, 100- and 200-day moving averages. Analyst consensus targets a price of roughly €106, implying upside of more than 35 percent from current levels, and not a single analyst covering the stock recommends selling. The market capitalisation of just under €20 billion, when set against €16.8 billion in cash, effectively prices the oncology pipeline at a few billion euros — a valuation that looks increasingly hard to defend given the breadth of late-stage data.
The bear case is not without merit. No oncology revenue is expected this year, and the path from clinical development to commercial sales takes years. The leadership change adds an element of uncertainty that good data alone cannot erase. But the investment thesis hinges on a longer timeframe: a company with €16.8 billion of financial firepower and 13 registration studies underway is being valued as if its pipeline will produce nothing. The strong ASCO readouts may not shift sentiment overnight, but they make that assumption steadily harder to maintain. The autumn data releases will be the real test of whether the oncology bet finally begins to deliver the re?rating the bulls have been waiting for.
Ad
BioNTech Stock: New Analysis - 16 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
